| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 30 Jan 2026 | 0001055947 |
| BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer | 30 Jan 2026 | 0000918923 |
| BVF I GP LLC | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 30 Jan 2026 | 0001803805 |
| BIOTECHNOLOGY VALUE FUND II LP | Other* | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer | 30 Jan 2026 | 0001102444 |
| BVF II GP LLC | Other* | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 30 Jan 2026 | 0001803806 |
| Biotechnology Value Trading Fund OS LP | Other* | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS | BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 30 Jan 2026 | 0001660683 |
| BVF Partners OS Ltd. | Other* | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS | Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 30 Jan 2026 | 0001660684 |
| BVF GP HOLDINGS LLC | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 30 Jan 2026 | 0001803809 |
| BVF INC/IL | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | BVF Inc., By: /s/ Mark N. Lampert, President | 30 Jan 2026 | 0001056807 |
| LAMPERT MARK N | 10%+ Owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO | /s/ Mark N. Lampert | 30 Jan 2026 | 0001233840 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPTX | Common Shares, no par value | Disposition pursuant to a tender of shares in a change of control transaction | -5,309,432 | -100% | 0 | 28 Jan 2026 | Direct | F1, F2, F3, F6 | ||
| transaction | RPTX | Common Shares, no par value | Disposition pursuant to a tender of shares in a change of control transaction | -4,308,573 | -100% | 0 | 28 Jan 2026 | Direct | F1, F2, F4, F6 | ||
| transaction | RPTX | Common Shares, no par value | Disposition pursuant to a tender of shares in a change of control transaction | -548,938 | -100% | 0 | 28 Jan 2026 | Direct | F1, F2, F5, F6 |
BVF PARTNERS L P/IL is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. |
| F2 | This Form 4 reports securities disposed of pursuant to an Arrangement Agreement, dated as of November 14, 2025, under the Business Corporations Act (Quebec), by and among the Issuer, XenoTherapeutics, Inc. ("Parent"), Xeno Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Parent, and solely for limited purposes, XOMA Royalty Corporation, pursuant to to which Purchaser acquired all of the issued and outstanding Common Shares of the Issuer, effective January 28, 2026 (the "Merger"). |
| F3 | Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. |
| F4 | Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. |
| F5 | Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. |
| F6 | The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments. |